Neogenomics Inc [NEO] stock is trading at $5.62, down -0.88%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NEO shares have gain 7.05% over the last week, with a monthly amount drifted -23.12%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neogenomics Inc [NASDAQ: NEO] stock has seen the most recent analyst activity on July 30, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, William Blair downgraded its rating to Mkt Perform on July 29, 2025. On May 15, 2025, Guggenheim initiated with a Neutral rating. Leerink Partners downgraded its rating to a Market Perform but stick to its price target of $9 on April 30, 2025. The Benchmark Company downgraded its rating to a Hold. Jefferies started tracking with a Buy rating for this stock on December 10, 2024, and assigned it a price target of $22.
Neogenomics Inc [NEO] stock has fluctuated between $4.72 and $19.11 over the past year. Currently, Wall Street analysts expect the stock to reach $9.33 within the next 12 months. Neogenomics Inc [NASDAQ: NEO] shares were valued at $5.62 at the most recent close of the market. An investor can expect a potential return of 66.01% based on the average NEO price forecast.
Analyzing the NEO fundamentals
Neogenomics Inc [NASDAQ:NEO] reported sales of 689.19M for the trailing twelve months, which represents a growth of 10.23%. Gross Profit Margin for this corporation currently stands at 0.44% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.12 and Total Capital is -0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Neogenomics Inc’s Current Ratio is 3.92. Also, the Quick Ratio is 3.58, while the Cash Ratio stands at 1.55. Considering the valuation of this stock, the price to sales ratio is 1.05, the price to book ratio is 0.85.
Transactions by insiders
Recent insider trading involved Kelly Michael Aaron, Director, that happened on May 27 ’25 when 5000.0 shares were purchased. Pres & Chief Operating Officer, Stone Warren completed a deal on May 12 ’25 to buy 5700.0 shares. Meanwhile, Director TETRAULT LYNN A. bought 7000.0 shares on May 09 ’25.
